R
Replimune Group, Inc.
REPL · NASDAQ · Healthcare · 1.3B
Price · close
$14.77
+5.12% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
8.2×
Enterprise value / EBITDAEV/EBITDA
-4.2×
Free cash flow yieldFCF yield
-20.8%
Return on equityROE
-188.9%
Operating margin
—
Net debt / EBITDAbalance-sheet strength
0.3×
Interest coverage
-36.1×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.